Changes in Body Composition and Cardiometabolic Risk Factors in Relation to the Reduction in Body Mass Index in Adolescents with Obesity

Teodoro Durá-Travé (✉ tduratra@cfnavarra.es)  
https://orcid.org/0000-0002-4628-2213

Fidel Gallinas-Victoriano  
Complejo Hospitalario de Navarra

María Malumbres-Chacón  
Complejo Hospitalario de Navarra

María Urretavizcaya-Martínez  
Complejo Hospitalario de Navarra

Paula Moreno-González  
Complejo Hospitalario de Navarra

Lotfi Ahmed-Mohamed  
Complejo Hospitalario de Navarra

Research

Keywords: Adolescents, Body mass index, Cardiometabolic risk factors, Lipid profile, Obesity

DOI: https://doi.org/10.21203/rs.3.rs-605508/v1

License: ☑️  This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background.** There are controversial data in relation to the reduction in BMI-SDS needed to improve adiposity in the pediatric population with obesity. The aim of this work is to determine the minimum variation in body mass index standard deviation score (BMI-SDS) required to improve the values of adiposity markers and cardiometabolic risk factors in growing adolescents with obesity.

**Methods.** A longitudinal study consisting in clinical evaluation (waist circumference, waist-to-height ratio and fat mass index, and blood pressure) and blood testing (insulin resistance and lipid profile) was conducted in 350 adolescents with obesity (152 boys and 198 girls), aged 10.2–14.3 years, that went through a combined intervention (12 months).

**Results.** A decrease in SDS-BMI ≤ 0.5 was not associated with any significant improvement in the clinical features and blood testing recorded. A decrease in BMI-SDS >0.5, and especially if >1.0, was linked to a significant improvement in adiposity markers. A decrease in BMI-SDS >0.5 was associated with a significant improvement in insulin resistance, and a decrease in BMI-SDS >1.0 was associated with a significant decrease in the percentage of patients who showed high values of systolic blood pressure, HOMA-IR and lipid profile.

**Conclusions.** Improvement in body composition, insulin resistance and lipid profile can be observed with reductions in BMI-SDS of ≥ 0.5 in obese adolescents, while extended benefits are obtained by losing at least 1.0 BMI-SDS.

Introduction

Childhood obesity has progressed in a sustained increase in most industrialized countries, and currently depicts the most relevant nutritional disorder in our environment [1, 2]. In addition, childhood obesity is related to a greater immediate risk of cardiometabolic complications in relation to adiposity, such as high levels of blood pressure, increased lipid serum concentration, insulin resistance (metabolic syndrome) and non-alcoholic fatty liver disease [3-7].

Waist circumference (WC) and waist-to-height ratio (WtHr) are good predictors of cardiovascular disease risk factors [8-10]. In spite of this, body mass index (BMI) has been frequently used in the diagnosis and follow up of children with obesity [11, 12] since it shows good correlation with body fat measured by Dual-energy X-ray absorptiometry (gold standard to define obesity) and cardiovascular risk factors [3, 13-16].

The implementation of a combined dietary-behavioral-physical activity intervention has proved to have a positive effect in adolescents with obesity. As body mass index SD score (BMI-SDS) decreases, so does fat mass in the absence of changes in fat-free mass and, consequently, in longitudinal growing [17, 18]. Despite this, there are controversial data in relation to the reduction in BMI-SDS needed to improve adiposity in the pediatric population with obesity. A recently published meta-regression study [19]
concluded that a minimum 0.6 decrease in BMI-SDS is imperative in order to attain any improvement in fat mass. Furthermore, a systematic review with meta-analysis [20] and several meta-regression studies [21, 22] concluded that reductions in BMI-SDS are likely to improve cardiovascular outcome in childhood and adolescent obesity; nevertheless, at present, they are unable to recommend a definite value of BMI-SDS reduction indispensable to improve markers of metabolic health. In other words, the reduction in BMI-SDS required to improve both body composition and the profile of cardiovascular risk factors by means of lifestyle interventions has not yet been fully established.

The objective of this study was the identification of the minimum change in BMI-SDS required to improve adiposity markers and cardiometabolic risk factors in adolescents with obesity enrolled in a combined intervention. We hypothesized that exclusive weight loss is not imperative in order to optimise body composition and cardiometabolic risk factors since, in accordance to the old aphorism: “the child becomes slim by means of keeping a stable weight because he/she is growing”.

**Material And Methods**

**Participants**

This is a longitudinal study (convenience sample) that was conducted in 350 adolescents (152 boys and 198 girls), aged 10.2 to 14.3 years and previously diagnosed with obesity (BMI-SDS >2.0). All patients included in the study were Caucasian and completed a clinical assessment (clinical evaluation was performed every 3 months) and blood testing before and after the participation in a one-year intervention program that comprises a combination of dietary-behavioral-physical activity. Medical attention was provided in the Pediatric Endocrinology Unit of the Navarra Hospital Complex (Pamplona, Spain), in the period January 2016-December 2019. All participants had previously experienced pubertal changes (Tanner stages: II-V). The exclusion criteria were obesity secondary to genetic, metabolic or endocrine disease.

Appropriate information on proceedings and potential implications was delivered to the parents and/or legal guardians, and the corresponding written consent was a requirement prior to the incorporation to this study in all cases. The study was then referred to the Ethics Committee for Human Investigation of Navarra Hospital Complex (in accordance with the ethical standards stated in the Declaration of Helsinki, 1964 and later amendments) for the final acceptance.

**Combined dietary-behavioral-physical activity intervention**

The combined intervention has been previously addressed [18, 23]. The thrust of the program corresponds to the axiom: “the child becomes slim by keeping a stable weight because he/she is growing” and it comprised nutritional education, nutritional intervention, the promotion of physical activity and healthy lifestyles.
The approach to maintaining current weight is achieved by means of a diversified and well-balanced diet for the entire family with no strict restrictions or immediate or excessive weight loss. The Mediterranean diet, adapted to family practices or the preferences of the participants, was the model diet.

Additionally, a personalized plan to encourage regular exercise was recommended to each individual and consisted of a daily, regulated (60 min) free-choice activity (cycling, swimming, martial arts, walking, etc.) and an increase in daily activity (such as walking, avoiding the use of the elevator, helping in house hold chores, etc.).

The participants were divided into four groups in line with the changes in BMI-SDS in the course of the combined intervention (between the beginning and after 12 months of follow-up):

- **Group I**: participants with increased BMI-SDS.
- **Group II**: participants with BMI SDS decreased by >0 to ≤0.5.
- **Group III**: participants with BMI SDS decreased by ›0.5 to ≤1.0.
- **Group IV**: participants with BMI SDS decreased by ›1.0 to ≤1.5.

**Clinical assessment**

The anthropometric measurements were taken following a protocol that had been previously published [18, 23]. The following anthropometric measurements were registered in the first appointment and every 3 months from there on: weight, height, skinfold thickness (biceps, triceps, subscapular and suprailiac) and waist circumference.

Individuals were disposed in underwear and barefoot in order to take weight and height measurements. Weight was determined using an Año-Sayol scale (reading interval 0 to 120 kg and a precision of 100 g), and height was measured using a Holtain wall stadiometer (reading interval 60 to 210 cm, precision 0.1 cm). BMI was calculated after applying the corresponding formula: weight (kg)/height$^2$ (m).

Skinfold thickness values were measured with an accuracy of 0.1mm on the left side of the body with Holtain skinfold calipers (CMS Weighing Equipment, Crymych, United Kingdom). The percentage of total body fat and fat mass (kg) was estimated using the equations reported by Slaughter et al., adjusted for sex and age [24]. The FMI was calculated using the following formula: fat mass (kg)/height$^2$ (m).

WC was quantified using a tape measure placed on a horizontal line equidistant from the last rib and the iliac crest, and the WtHR was calculated in accordance to the formula: waist (m)/height (m). All these measurements were reported by the same trained individual.

The SDS values for weight, height, BMI and WC were quantified using the program *Aplicación Nutricional*, from the Spanish Society of Pediatric Gastroenterology, Hepatology and Nutrition (Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica, available at  http://www.gastroinf.es/nutritional/).
The graphics from Ferrández et al. (Centro Andrea Prader, Zaragoza 2002) were the reference charts for this assessment [25].

The individuals were placed in the supine position, in order to measure blood pressure (BP) in the right arm, using a Visomat comfort 20/40 (Roche Diagnostics Inc., Amman, Jordan) digital blood pressure monitor, selecting the lowest of three measurements. Arterial hypertension was defined when systolic (SBP) and/or diastolic pressure (DBP) was equal to or higher than the 95th percentile by age, sex, and height, in accordance to the American reference charts (National high blood pressure Program in Children and Adolescents) [26].

**Blood testing**

Fasting glucose, insulin, triglycerides (TGC), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were determined in the course of the combined intervention (at the onset and after 12 months of follow-up), by means of standardized methodologies. In accordance to the International Diabetes Federation consensus report for children and adolescents [27], serum TC levels higher than 200 mg/dL, TGC levels higher than 150 mg/dL, LDL-C levels higher than 130 mg/dL, or HDL-C levels lower than 40 mg/dL were accepted as dyslipidemia, and fasting blood glucose higher than 100 mg/dL as dysglycaemia.

The HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) indexes were calculated from fasting glucose and insulin concentrations (fasting glucose in mmol/L x fasting insulin in mU/L)/22.5) with the aim to assess insulin resistance. An HOMA-IR value equal to or higher than 4.0 was considered to be insulin resistance [28].

**Statistical Analysis**

Results are displayed as percentages (%) and means (M), with their pertaining standard deviations (SDS). Chi-square test was used to compare percentages within and between groups according to changes in BMI SDS. Student’s t-test was used to compare mean values in the variables recorded within groups. ANOVA was used to compare mean values in variables between groups. Pearson’s test was used to quantify the degree of linear association between quantitative variables. Statistical analyses were performed using the program Statistical Packages for the Social Sciences version 20.0 (Chicago, IL, USA). Statistical significance was accepted when P-value was <0.05.

**Results**

The mean values of clinical and biochemical features registered in individuals of both sexes before the implementation of the combined intervention are displayed in table 1, as well as the comparison. Mean values of age, weight, height, BMI and waist were significantly higher in boys (p < 0.01). There were no significant differences in the mean values of weight-SDS, height-SDS, BMI-SDS, WC-SDS, WtHr and FMI,
as well as in the SBP or DBP, and the biochemical characteristics registered between the participants of both sexes.

At baseline, there was a statistically significant positive correlation (p<0.01) between BMI-SDS and FMI (boys: r = 0.899, girls: r = 0.829), WC-SDS (boys: r = 0.913, girls: 0.824) and WtHr (boys: r = 0.843, girls: r = 0.830).

The mean initial and final values for weight and BMI-SDS of these groups are shown in table 2. The comparison of the groups confirmed that there were no significant differences between the mean values of both weight and BMI-SDS at the onset of the combined intervention. There were no significant differences in the changes in weight at 12 months follow-up in the groups with a decrease in BMI-SDS. (groups I, II and III).

The modifications in clinical features in relation to variations in BMI-SDS at 12-month follow-up are shown in Table 3. The comparison of the groups uncovered no significant differences in any of the clinical features registered at the onset of the combined intervention. However, at 12 months of follow-up, the analysis identified that a decrease in BMI-SDS had was related to a significant decrease in WC-SDS, WtHR and FMI, while height-SDS and SBP and DBP revealed a non-significant decrease (ANOVA). In group I patients, the increase in BMI-SDS was linked to a significant increase in WC-SDS, FMI and SBP, while height-SDS, WtHR and DBP showed a non-significant increase. A decrease in SDS-BMI by >0 to ≤0.5 (group II) was not associated with any significant decrease in any of the clinical features recorded (height-SDS, WC-SDS, WtHR, FMI, and SBP and DBP). A decrease in SDS-BMI by >0.5 to ≤1.0 (group III) was associated with a significant decrease in WC-SDS, WtHR and FMI, while height-SDS, SBP and DBP showed a non-significant decrease. Finally, a decrease in SDS-BMI by >1.0 to ≤1.5 (group IV) was related to a significant decrease in WC-SDS, WtHR, FMI and SBP, while height-SDS and DBP showed a non-significant decrease. There were no significant differences in the variations in clinical features in relation to changes in BMI-SDS at 12-month follow-up between boys and girls.

Modifications in biochemical characteristics in relation to changes in BMI-SDS at 12-month follow-up are exposed in Table 4. The comparison of the groups at the onset of the combined intervention revealed no significant differences in any of the biochemical characteristics recorded. However, at 12 months of follow-up, the analysis evinced that a decrease in BMI-SDS was related to a significant decrease in insulin, HOMA-IR tryglicerides, TC and LDL-C, while HDL-C showed a non-significant decrease (ANOVA). In group I patients, the increase in BMI-SDS did not entail any significant decrease in each of the biochemical characteristics recorded (glucose metabolism and lipid profile). In group II patients, the decrease in BMI-SDS (from >0 to ≤0.5) was not related to any significant decrease in each of the recorded biochemical characteristics either (glucose metabolism or lipid profile). And finally, a decrease in SDS-BMI by >0.5 to ≤1.0 (group III) or by >1.0 to ≤1.5 (group IV) was related to a significant decrease in glucose, insulin, HOMA-IR and TGC, while TC, LDL-C and HDL-C showed a non-significant decrease. There were no significant differences in the changes in glucose metabolism and lipid profile in relation to changes in BMI-SDS at 12 months follow-up between boys and girls.
Changes in percentage values for the cardiometabolic risk factors in relation to changes in BMI-SDS at 12-month follow-up are shown in Table 5. The comparison of the groups at the beginning of the combined intervention exhibits no significant differences in each of the cardiometabolic risk factors recorded (SBP and DBP, HOMA-IR and lipid profile). However, at 12 months of follow-up, it was observed that a decrease in BMI-SDS was associated with a significant decrease in the percentage of patients who showed SBP values higher than 95th percentile for the applied reference, as well as percentages of HOMA-IR index values higher than 4.0, plasma TGC higher than 150 mg/dl, TC higher than 200 mg/dl, LDL-C higher than 130 mg/dl and HDL-C values lower than 40 mg/dl; simultaneously; DBP values higher than 95th percentile for the applied reference showed a non-significant decrease. In group I patients, the increase in BMI-SDS was not associated with any significant decrease in percentage of patients who showed high values in DBP, HOMA-IR index and lipid profile; however, the percentage of patients with higher values in SBP showed a significant increase. In group II patients, the decrease in BMI-SDS (from <0 to > 0.5) was not associated with any significant decrease in percentage of patients who showed high values in SBP and DBP, HOMA-IR index and lipid profile, but the percentage of patients with HDL-C values lower than 40 mg/dl showed a significant decrease. In group III patients, the decrease in BMI-SDS (from >0.5 to ≤1.0) was not associated with any significant decrease in the percentage of patients who showed high values in SBP and DBP; at the same time, the percentage of patients with higher values in HOMA-IR index and lipid profile, except in LDL-C, experienced a significant decrease. And finally, a decrease in SDS-BMI by >1.0 to ≤1.5 (group IV) was associated with a significant decrease in the percentage of patients who showed high values of SBP, HOMA-IR and lipid profile, while the percentage of patients with higher values in DBP showed a non-significant increase. There were no significant differences in the changes in percentages of the cardiometabolic risk factors recorded in relation to changes in BMI SDS at 12 month period of follow-up between boys and girls.

Discussion

This study features that a significant improvement in body composition and cardiovascular risk factors associated with obesity is observed in adolescents with obesity when BMI-SDS decreases at least 0.5 in a 12-month period, and, especially, when the decrease is greater than 1.0. In our experience, losing weight would not be necessary, since, in accordance with the old aphorism: “the child becomes slim by means of keeping a stable weight because he/she is growing” [18, 23].

This study was designed on the basis of previous data regarding the change in BMI-SDS required to reduce adiposity or to improve cardiovascular outcome in children and adolescents with obesity through lifestyle interventions [28-30]. Nevertheless, it differs from previous reports since the sample is much larger and the definition of the groups in relation to the decrease in BMI-SDS is distinct. And, above all, because those studies were based on weight loss as a condition to achieve an improvement in body composition (decrease in adiposity) and modify the profile of cardiovascular risk factors associated with obesity [19-22, 28, 29, 31].
One of the main objectives in the treatment of childhood obesity is to reduce the percentage of body fat mass without negatively affecting longitudinal growth. In compliance with several authors, our experience leads us to consider that maintaining a constant weight during a combined intervention in a growing adolescent would be sufficient to reduce BMI-SDS and, consequently, to decrease body fat without altering growth [14, 18, 23, 31, 32]. Dual-energy X-ray absorptiometry (DEXA) has been considered as “quasi gold standard” to define obesity [33], but its complex and expensive use makes it not feasible for daily clinical practice or epidemiological research. Anthropometric measures such as BMI, WC, WtHr, and FMI have been used as alternatives, as they are readily available and can serve as inexpensive tools to identify obesity [8-10, 34-37]. A recently published systematic review and meta-analysis found that both BMI and WtHr were strongly correlated with body fat measured by DEXA; therefore, both could be used to diagnose obesity in pediatric populations when more sophisticated techniques are not available [16]. In this study, BMI was applied for the definition of obesity, despite its limitations (it does not differentiate between fat mass and fat-free mass), precisely because it correlates well with body fat and cardiovascular risk factors [3, 13-15, 34]. It is noteworthy that in this study we also found a significant correlation between the BMI-SDS values and the adiposity parameters recorded (WC-SDS, WtHr and FMI).

In the present study we observed no improvement in body composition parameters and cardiovascular risk factors associated with obesity (hypertension, increase in HOMA-IR, TGC, TC and LDL-C, and decrease in HDL-C) with a BMI-SDS decrease lower than 0.5 in a 12 month period. In contrast with previous studies [28-30], we found that an improvement in body composition and some cardiometabolic risk factors associated with obesity (decrease in HOMA-IR and TGC) can be noticed with BMI-SDS reductions by >0.5 to ≤1.0 in adolescents with obesity, but the reduction in BMI-SDS required to simultaneously improve body composition and cardiovascular outcomes in adolescents with obesity (decrease in hypertension, HOMA-IR, TGC, TC and LDL-C, and increase in HDL-C) should be greater than 1.0.

On the other hand, our results corroborate that a reduction in BMI-SDS greater than 0.5 can be achieved if weight remains practically stable for a period of 1 year in growing adolescents with obesity under a combined program of physical activity intervention [18, 23]. In fact, 36% of participants in this study (group III and IV) achieved a reduction in BMI by >0.5 to ≤1.0, and in 16% (group IV) the reduction was greater than 1.0. That is to say, to reduce adiposity in this patients it would not be necessary to force a weight loss that could condition their linear growth, but rather it would be enough to comply with the aphorism taken as a reference in this study.

Insulin resistance is considered as the determining pathogenic factor in the onset of lipid profile and lipoprotein alterations that are highly atherogenic and concur in obesity. The insulin resistance induces hypertriglyceridermia and, consequently, a higher proportion of low density lipoproteins, as well as a decline in the formation of high density lipoproteins, with capacity of endothelial toxicity and deposit in arterial wall [3-7, 38, 39]. A balanced diet and increased physical activity are known to improve dyslipidemia; therefore, a reasonable strategy in obese patients would be lifestyle interventions such as maintaining an adequate diet and physical activity. In fact, the observed changes in body composition
and cardiometabolic risk factors in relation to the reduction in BMI-SDS in our sample of adolescents with obesity represented the effects of a combined intervention, which included nutritional education, a balanced diet and lifestyle modification through increased physical activity [14, 18, 23, 40-42].

Conclusions

Our findings indicate that, the maintenance of a constant weight in growing adolescents, a reduction in BMI-SDS greater than 0.5, and, especially, if the decrease is greater than 1.0, are associated with improvements in body composition, insulin resistance and lipid profile. However, more evidence is needed before such parameters can be identified and used in a clinical setting.

Declarations

Ethical Approval and Consent to participate

This study was approved by the Ethics Committee for Human Investigation of the Navarra Hospital Complex, Pamplona, Spain (in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and later amendments).

Parents and/or legal guardians were informed and provided consent for the participation in this study in all cases.

Consent for publication

All authors have given consent for the paper to be published by the corresponding author.

Availability of supporting data

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing Interests. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article (none declared).

Funding. The authors received no financial support for the research, authorship, and/or publication of this article (none declared).

Authors’ contributions. TDT and FGV participated in study design and data analysis, and wrote the first draft of the manuscript. MMC, MUM, PMG and LAM participated in data collection and analysis. All authors participated in manuscript preparation and approved its final version.

Acknowledgements

Not applicable
Authors’ information

Not applicable

References

1. Lissau I, Overpeck MD, Ruan WJ, Due P, Holstein, Hediger ML. Body mass index and overweight in adolescents in 13 European countries, Israel, and the United States. Arch Pediatr Adolesc Med. 2004;158:27-33.

2. Cheung PC, Cunningham SA, Venkat Naryan KM, Kramer MR. Childhood Obesity Incidence in the United States: A Systematic Review. Childhood Obesity 2016;12:1-11.

3. Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr 2007;150:12.e2-17.e2.

4. Mattsson N, Rönnemaa T, Juonala M, Viikari JSA, Raitakari OT. Childhood predictors of the metabolic syndrome in adulthood. The Cardiovascular Risk in Young Finns Study. Ann Med. 2008:40:542–552.

5. Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011:365:1876-1885.

6. Kelly AS, Barlow SE, Rao G, Inge TH, Hayman L, Steinberger J, et al. Severe obesity in children and adolescents: Identification, associated health risks, and treatment approaches: A scientific statement from the American heart association. Circulation. 2013:128:1689–1712.

7. Velfer YA, Phillip M, Shalitin S. Increased prevalence of severe obesity and related comorbidities among patients referred to a pediatric obesity clinic during the last decade. Horm Res Paediatr. 2019:92:169-178.

8. Savva SC, Tornaritis M, Savva ME, Kourides, Y, Panagi A, Silikiotou N, et al. Waist circumference and waist-to-height ratio are better predictors of cardiovascular disease risk factors in children than body mass index. Int J Obes Relat Metab Disord. 2000;24:1453–1458.

9. Kelishadi R, Gheiratmand R, Ardalan G, Adeli K, Mehdi Gouya M, Mohammad Razaghi E, et al. Association of anthropometric indices with cardiovascular disease risk factors among children and adolescents: CASPIAN Study. Int J Cardiol. 2007:117:340–348.

10. Fraporti MI, Scherer-Adami F, Dutra-Roselen M. Cardiovascular risk factors in children. Rev. Port. Cardiol. 2017:36:699–705.

11. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin
Endocrinol Metab. 2017:102:709-57.

12. Kumaran A, Sakka S, Renuka P, Dias RP. Obesity in children: recent NICE guidance. Arch Dis Child Educ Pract Ed. 2017;102:84–88.

13. Daniels SR, Jacobson MS, McCrindle BW, Eckel RH, Sanner BM. American Heart Association Childhood Obesity Research Summit Report. Circulation. 2009;119:e489–e517.

14. De Miguel-Etayo P, Moreno LA, Santabarbara J, Martin-Matillas M, Piqueras MJ, Rocha-Silva D, et al. Anthropometric indices to assess body-fat changes during a multidisciplinary obesity treatment in adolescents: EVASYON Study. Clin Nutr 2015;34:523–528.

15. Jensen NS, Camargo TF, Bergamaschi DP. Comparison of methods to measure body fat in 7-to-10-year-old children: A systematic review. Public Health. 2016;133:3–13.

16. Martin-Calvo N, Moreno-Galarraga L, Martinez-Gonzalez MA. Association between body mass index, waist-to-height ratio and adiposity in children: A systematic review and meta-analysis. Nutrients. 2016;20:8.

17. De Miguel-Etayo P, Moreno LA, Iglesia I, Bel-Serrat S, Mouratidou T, Garagorri JM. Body composition changes during interventions to treat overweight and obesity in children and adolescents; a descriptive review. Nutr Hosp. 2013;28:52–62.

18. T. Durá-Travé T, Gallinas-Victoriano F, Urretavizcaya-Martinez M, Ahmed-Mohamed L, Chueca-Guindulain MJ, Berrade-Zubiri S. Effects of the application of a prolonged combined intervention on body composition in adolescents with obesity. Nutr J. 2020:19:49.

19. Birch L, Perry R, Hunt LP, Matson R, Chong A, Beynon R, et al. What change in body mass index is associated with improvement in percentage body fat in childhood obesity? A meta-regression. BMJ Open. 2019:9: e028231.

20. Ho M, Garnett SP, Baur L, Burrows T, Stewart L, Neve M, et al. Effectiveness of lifestyle interventions in child obesity: systematic review with meta-analysis. Pediatrics. 2012:130:e1647–e1671.

21. Matson RI, Perry R, Hunt LP, Chong AH, Beynon R, Hamilton-Shield J, et al. Change in obesity-related metabolic abnormalities associated with body mass index improvement through life-style intervention: A meta-regression. Pediatr Diabetes. 2020:21:173-193.

22. El-Medany AYM, Birch L, Hunt LP, Matson R, Chong AHW, Beynon R, et al. What change in body mass index is required to improve cardiovascular outcomes in childhood and adolescent obesity through lifestyle interventions: A meta-regression. Child Obes. 2020;16:449-478.

23. Durá-Travé T. Gallinas-Victoriano F, Urretavizcaya-Martinez M, Ahmed-Mohamed L, Chueca-Guindulain MJ, Berrade-Zubiri S. Assessment of body composition changes during a combined
intervention for the treatment of childhood obesity. Nutrition. 2019;59:116–120.

24. Slaughter MH, Lohman TG, Boileau RA, Horswill CA, Stillman RJ, van Loan MD, et al. Skinfold equations for estimation of body fatness in children and youths. Hum Biol. 1988;60:709–723.

25. Ferrandez A, Baguer L, Labarta JL, Labena C, Mayayo E, Puba B. Longitudinal pubertal growth according to age at pubertal study of normal Spanish children from birth to adulthood. Pediatr Endocr Rev. 2005;2:423–559.

26. Horan MJ, Sinaiko AR. Synopsis of the Report of the second task force on blood pressure control in children. Hypertension. 1987;10:115-121.

27. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents-an IDF consensus report. Pediatr. Diabetes 2007;8:299-306.

28. Reinehr T, Kiess W, Kapellen T, Andler W. Insulin sensitivity among obese children and adolescents, according to degree of weight loss. Pediatrics. 2004;114:1569–1573.

29. Reinehr T, Andler W. Changes in the atherogenic risk factor profile according to degree of weight loss. Arch Dis Child. 2004;89:419–422.

30. Ford AL, Hunt LP, Cooper A, Shield JP. What reduction in BMI SDS is required in obese adolescents to improve body composition and cardiometabolic health? Arch Dis Child. 2010;95:256–261.

31. Parks EP, Zemel B, Moore RH, Berkowitz RI. Change in body composition during a weight loss trial in obese adolescents. Pediatr Obes. 2014;9:26–35.

32. Moreno LA, Ochoa MC, Warnberg J, Marti A, Martinez JA, Marcos A. Treatment of obesity in children and adolescents. How nutrition can work? Int J Pediatr Obes. 2008;3(suppl 1):72–77.

33. Shepherd JA, Ng BK. Sommer MJ, Heymsfield SB. Body composition by DXA. Bone 2017:104:101-105.

34. Hunt LP, Ford A, Sabin MA, Crowne EC, Shield JPH. Clinical measures of adiposity and percentage fat loss: which measure most accurately reflects fat loss and what should we aim for? Arch Dis Child. 2007;92:399–403.

35. Zhou D, Yang M, Yuan ZP, Zhang DD, Liang L, Wang CL, et al. Waist-to height ratio: a simple, effective and practical screening tool for childhood obesity and metabolic syndrome. Prev Med. 2014;67:35–40.

36. Mehta SK. Waist circumference to height ratio in children and adolescents. Clin Pediatr (Phila.). 2015;54:652–658.

37. Javed A, Jumean M, Murad MH, Okorodudu D, Kumar S, Somers VK, Javed, A et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and
adolescents: a systematic review and meta-analysis. Pediatr. Obes. 10: 234–244 (2015).

38. Ascaso J, Gonzalez-Santos P, Hernandez-Mijares A, Mangas-Rojas A, Masana L, Millan J, et al. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum. Am J Cardiovasc Drugs. 2007;7:39-58.

39. Skinner AC, Perrin EM, Moss LA, Skelton JA. Cardiometabolic Risks and Severity of Obesity in Children and Young Adults. N Engl J Med. 2015;373:1307–1317.

40. Harada-Shiba M, Ohta T, Ohtake A, Ogura M, Dobashi K, Nohara A, et al. Guidance for pediatric familial hypercholesterolemia 2017. J. Atheroscler Thromb. 2018;25:539-553.

41. Barker AR, Gracia-Marco L, Ruiz JR, Castillo MJ, Aparicio-Ugarriza R, González-Gross M, et al. Physical activity, sedentary time, TV viewing, physical fitness and cardiovascular disease risk in adolescents. The HELENA study. Int J Cardiol. 2018;254:303-309.

42. Hajna A, Ross NA, Dasgupta K. Steps, moderate-to-vigorous physical activity, and cardiometabolic profiles. Prev Med. 2018;107:69-74.

**Tables**

Table 1. Clinical and biochemical data before combined intervention in both sexes (mean±SD)

---

Page 13/21
| Characteristics            | All (n=350) | Boys (n=152) | Girls (n=198) | p-value* |
|---------------------------|-------------|--------------|---------------|----------|
| **Clinical data**         |             |              |               |          |
| Age (years)               | 12.1±1.6    | 12.5±1.5     | 11.7±1.8      | P<0.01   |
| Weight (kg)               | 69.9±13.8   | 76.2±14.1    | 65.1±11.9     | p<0.01   |
| Weight-SDS                | 2.94±1.12   | 3.14±0.96    | 2.92±0.88     | N.S.     |
| Height (cm)               | 155.5±10.6  | 159.3±10.9   | 152.5±9.6     | p<0.01   |
| Height-SDS                | 0.82±0.91   | 0.88±0.91    | 0.76±0.81     | N.S.     |
| BMI (kg/m²)               | 28.4±3.8    | 29.4±3.9     | 27.6±3.5      | p<0.01   |
| BMI-SDS                   | 3.05±1.01   | 3.36±0.99    | 2.88±0.98     | N.S.     |
| WC (cm)                   | 92.6±9.1    | 97.6±9.2     | 89.7±8.2      | p<0.01   |
| WC-SDS                    | 2.40±0.9    | 2.85±0.91    | 2.44±0.84     | N.S.     |
| WtHr                       | 0.59±0.05   | 0.61±0.04    | 0.59±0.05     | N.S.     |
| FMI (kg/m²)               | 10.7±2.0    | 10.6±2.0     | 10.7±1.8      | N.S.     |
| **Systolic BP (mmHg)**    | 123.1±11.4  | 124.9±11.3   | 122.0±11.9    | N.S.     |
| **Diastolic BP (mmHg)**   | 70.2±8.6    | 70.4±8.5     | 70.2±9.1      | N.S.     |
| **Laboratory data**       |             |              |               |          |
| Fasting glucose (mg/dL)   | 87.5±6.7    | 88.6±7.4     | 86.6±7.0      | N.S.     |
| Insulin (mU/L)            | 19.7±9.1    | 18.1±9.8     | 20.9±12.1     | N.S.     |
| HOMA-IR                   | 4.28±2.19   | 3.99±2.22    | 4.51±2.9      | N.S.     |
| Triglycerides (mg/dL)     | 106.7±37.6  | 104.0±35.7   | 110.3±39.4    | N.S.     |
| Total cholesterol (mg/dL) | 164.6±27.1  | 167.4±31.9   | 162.4±24.7    | N.S.     |
| HDL-C (mg/dL)             | 44.8±8.2    | 45.7±8.1     | 44.2±8.3      | N.S.     |
| LDL-C (mg/dL)             | 100.1±23.5  | 102.3±25.1   | 98.1±21.3     | N.S.     |

*Student’s t-test

BMI: body mass index. WC: waist circumference. WtHR: waist-to-height ratio. FMI: fat mass index. BP: Blood pressure. HOMA-IR: homeostasis model assessment of insulin resistance. HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol
Table 2. Groups formed in relation to changes in BMI-SDS at 12-month follow-up.

| Variable       | Group I (Increased) (n=156) | Group II (Decreased >0 to ≤0.5) (n=68) | Group III (Decreased >0.5 to ≤1.0) (n=70) | Group IV (Decreased >1.0 to ≤1.5) (n=56) | p-values* |
|----------------|----------------------------|----------------------------------------|------------------------------------------|------------------------------------------|-----------|
| Boys/girls     | 76/80                      | 30/38                                  | 26/44                                    | 20/36                                    |           |
| Weight (kg)    |                            |                                        |                                          |                                          |           |
| Initial mean   | 71.1±14.7                  | 70.6±14.7                              | 71.4±15.8                                | 70.2±12.1                                | N.S.      |
| Final mean     |                            |                                        |                                          |                                          |           |
| p-value**      |                            |                                        |                                          |                                          |           |
|                | 2.91±0.91                  | 3.00±0.93                              | 3.10±0.81                                | 3.12±0.84                                | N.S.      |
| BMI (SDS)      | 3.50±1.10                  | 2.77±1.10                              | 2.25±0.78                                | 1.96±0.79                                | p<0.01    |
| Initial mean   |                            |                                        |                                          |                                          |           |
| Final mean     |                            |                                        |                                          |                                          |           |
| p-value**      |                            |                                        |                                          |                                          |           |
|                | 0.63±0,39                  | -0,23±0.12                             | -0,85±0.22                               | -1,35±0.15                               | p<0.01    |
| BMI change     | (range)                    |                                        |                                          |                                          |           |

*ANOVA. **Student's t-test

BMI: body mass index.

Table 3. Changes in clinical characteristics according to changes in BMI SDS at 12-month follow-up.
| Variable | Group I (Increased) (n=156) | Group II (Decreased >0 to \( \leq 0.5 \)) (n=68) | Group III (Decreased >0.5 to \( \leq 1.0 \)) (n=70) | Group IV (Decreased >1.0 to \( \leq 1.5 \)) (n=56) | p-values* |
|----------|--------------------------|--------------------------|--------------------------|--------------------------|-----------|
| Height (SDS) Initial mean | 0.73±0.91 | 0.79±0.91 | 0.67±0.98 | 0.66±0.94 | N.S. |
|          Final mean | 0.70±1.07 | 0.75±1.11 | 0.65±1.09 | 0.65±0.97 | N.S. |
| WC-SDS Initial mean | 2.45±1.25 | 2.46±0.93 | 2.44±1.2 | 2.47±1.38 | N.S. |
|          Final mean | 2.84±1.21 | 2.47±0.99 | 1.85±1.2 | 1.80±1.31 | p<0.01 |
| WtHr Initial mean | 0.59±0.05 | 0.59±0.04 | 0.60±0.05 | 0.60±0.06 | N.S. |
|          Final mean | 0.61±0.09 | 0.59±0.05 | 0.57±0.07 | 0.57±0.07 | p=0.03 |
| FMI (kg/m\(^2\)) Initial mean | 10.7±2.1 | 10.6±2.1 | 11.1±2.0 | 10.9±2.3 | N.S. |
|          Final mean | 11.3±1.8 | 10.3±2.2 | 10.0±2.4 | 9.6±2.0 | p<0.01 |
| Systolic BP Initial mean | 122.2±13.3 | 121.6±11.5 | 124.7±11.9 | 126.4±10.4 | N.S. |
|          Final mean | 126.9±14.1 | 121.4±12.6 | 123.1±10.1 | 122.1±8.5 | N.S. |
|          | Diastolic BP | Initial mean | Final mean | p-value** |
|----------|--------------|--------------|------------|-----------|
|          | Final mean   |              |            |           |
|          | 70.7±9.1     | 68.5±8.9     | 71.7±9.1   | 71.1±9.2  | N.S.      |
|          | 72.2±9.7     | 68.5±6.8     | 70.4±9.8   | 70.7±9.9  | N.S.      |
|          | N.S.         | N.S.         | N.S.       | N.S.      |           |

*ANOVA. **Student’s t-test

WC: waist circumference. WtHR: waist-to-height ratio. FMI: fat mass index. BP: blood pressure.

Table 4. Changes in glucose metabolism and lipid profile in relation to changes in BMI SDS at 12 months follow-up.
| Variable | Group I (Increased) (n=156) | Group II (Decreased >0 to ≤0.5) (n=68) | Group III (Decreased >0.5 to ≤1.0) (n=70) | Group IV (Decreased >1.0 to ≤1.5) (n=56) | p-values* |
|----------|----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------|
| Glucose (mg/dL) | | | | | |
| Initial mean | 87.6±8.2 | 85.3±5.9 | 88.7±7.1 | 88.7±8.0 | N.S. |
| Final mean | 87.2±6.9 | 86.7±6.7 | 84.1±7.0 | 83.0±6.81 | N.S. |
| p-value** | N.S. | N.S. | P=0.01 | P<0.01 | |
| Insulin (mU/L) | | | | | |
| Initial mean | 19.2±12.5 | 20.0±13.4 | 22.0±17.5 | 21.8±19.0 | N.S. |
| Final mean | 21.1±13.4 | 21.6±14.6 | 14.6±13.5 | 14.9±10.9 | p=0.03 |
| p-value** | N.S. | N.S. | P<0.01 | P<0.01 | |
| HOMA-IR | | | | | |
| Initial mean | 4.2±2.1 | 4.3±2.5 | 4.8±3.1 | 4.7±3.5 | N.S. |
| Final mean | 4.65±2.5 | 4.47±2.4 | 2.65±2.1 | 2.3±1.7 | p<0.01 |
| p-value** | N.S. | N.S. | P<0.01 | P<0.01 | |
| Tryglicerides | | | | | |
| Initial mean | 100.5±33.2 | 104.8±35.9 | 108.3±36.5 | 105.2±33.9 | N.S. |
| Final mean | 105.7±37.6 | 112.4±39.7 | 89.3±29.9 | 86.3±27.6 | p=0.01 |
| p-value** | N.S. | N.S. | P<0.01 | P<0.01 | |
| TC (mg/dL) | | | | | |
| Initial mean | 167.4±28.8 | 163.2±29.1 | 163.3±29.5 | 161.8±28.1 | N.S. |
| Final mean | 166.3±26.1 | 166.8±29.5 | 154.5±29.9 | 153.3±21.9 | p<0.01 |
| p-value** | N.S. | N.S. | N.S. | N.S. | |
| HDL-C (mg/dL) | | | | | |
| Initial mean | 45.8±9.5 | 43.2±8.5 | 44.2±8.9 | 44.0±8.4 | N.S. |
| Final mean | 44.1±8.3 | 44.5±6.6 | 46.0±8.3 | 44.6±4.7 | N.S. |
Table 5. Changes in percentage of cardiometabolic risk factors in relation to changes in BMI SDS at 12 month follow-up.

| LDL-C (mg/dL) | Initial mean | Final mean | p-value** |
|---------------|--------------|------------|-----------|
|               | 101.7±18.5   | 102.9±17.4 | N.S.      |
|               | 100.2±17.8   | 101.1±18.4 | N.S.      |
|               | 99.9±18.9    | 94.5±17.0  | N.S.      |
|               | 95.3±18.8    | 93.2±15.7  | p<0.05    |

**ANOVA. **Student's t-test

HOMA-IR: Homeostasis Model Assessment of Insulin Resistance. TC: total cholesterol. HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol
| Variable | Group I (Increased) (n=156) | Group II (Decreased >0 to ≤ 0.5) (n=68) | Group III (Decreased >0.5 to ≤ 1.0) (n=70) | Group IV (Decreased >1.0 to ≤ 1.5) (n=56) | p-value* |
|----------|-----------------------------|----------------------------------------|---------------------------------------------|---------------------------------------------|----------|
| SBP >95th Initial mean | 24 (21.8%) | 12 (23.1%) | 14 (26.9%) | 12 (28.6%) | N.S. |
| | 38 (33.9%) | 8 (15.4%) | 10 (25%) | 0 (0%) | p<0.01 |
| | P<0.05 | N.S.. | N.S.. | P<0.01 | |
| p-value** | | | | | |
| DBP >95th Initial mean | 5 (4.5%) | 3 (5.7%) | 3 (5.7%) | 3 (7.1%) | N.S. |
| | 5 (4.5%) | 2 (3.8%) | 2 (3.8%) | 2 (4.7%) | N.S. |
| | N.S.. | N.S.. | N.S.. | N.S.. | |
| p-value** | | | | | |
| HOMA-IR >4.0 Initial mean | 60 (41.1%) | 30 (41.7%) | 32 (50%) | 198 (39.6%) | N.S. |
| | 66 (44.6%) | 28 (37.8%) | 8 (12.1%) | 6 (14.2%) | p<0.01 |
| | N.S.. | N.S.. | P<0.01 | P<0.01 | |
| p-value** | | | | | |
| TGC >150 mg/dl Initial mean | 28 (18.7%) | 18 (24.3%) | 16 (25%) | 12 (25%) | N.S. |
| | 26 (17.6%) | 12 (16.2%) | 6 (9.1%) | 0 (0%) | p<0.01 |
| | N.S.. | N.S.. | P<0.05 | P<0.01 | |
| p-value** | | | | | |
| TC >200 mg/dL | 22 (14.1%) | 10 (13.2%) | 10 (14.7%) | 6 (12.5%) | N.S. |
|                | Initial mean | Final mean | p-value** |
|----------------|--------------|------------|-----------|
| **HDL-C <40 mg/dL** | 54 (36.5%) | 30 (40.5%) | N.S.     |
|                | 53 (35.8%)   | 18 (24.3%) | P<0.05   |
| **LDL-C >130 mg/dL** | 22 (14.9%) | 8 (10.8%)  | N.S.     |
|                | 22 (14.9%)   | 8 (10.8%)  | P<0.05   |

*χ² inter-groups.  **χ² intra-groups

SBP: systolic blood pressure. DBP: diastolic blood pressure. HOMA-IR: homeostasis model assessment of insulin resistance. TGC: tryglicerides. TC: total cholesterol. HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol.